medigraphic.com

2011, Number 3

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2011; 49 (3)

Elevated liver enzymes, impaired fasting glucose and undiagnosed diabetes

González-Pérez B, Salas-Flores R, Echegollen-Guzmán A, Pizarro-Chávez S, Arístides Guillén-Mata G

Language: Spanish
References: 31
Page: 247-257
PDF size: 38.63 Kb.


ABSTRACT

Background: emerging evidence suggests that elevated liver enzymatic activity is associated with diabetes. The purpose was to investigate the prevalence of elevated liver enzymes and its relationship between impaired fasting glucose (IFG) and undiagnosed diabetes in family medicine practice.
Methods: a cross-sectional prospective analytic study was conducted in a representative sample of 100 patients aged 25 to 60 years who underwent to a screening for diabetes. Risk factors, BMI, waist circumference, blood pressure, fasting glucose, lipid profile, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltransferase (GGT) and C-reactive protein were evaluated. The relationships between liver enzymes, undiagnosed diabetes and IFG were analyzed through χ2 and Student’s t test to identify differences in continuous variables.
Results: the prevalence found in undiagnosed diabetes were ALT 16.9 %, AST 15.8 % and GGT 20.6 % and in IFG were 76.3 %, 68.4 % and 77.8 % respectively. The relationships between elevated ALT (0.001) and GGT (0.000) with undiagnosed diabetes and IFG were statistically significant.
Conclusion: elevated ALT or GGT raise the possibility of undiagnosed type 2 diabetes mellitus in family practice.


REFERENCES

  1. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne P et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344(18): 1343-1350.

  2. World Health Organization. Report of a World Health Organization and International Diabetes Federation meeting: screening for type 2 diabetes. Geneva: World Health Organization; 2003.

  3. Rivera J, Cuevas L, Shamah T, Villalpando S, Ávila MA, Jiménez A. Nutritional Status. National Survey of Health Nutrition 2006. Cuernavaca, Morelos, México: Instituto Nacional de Salud Pública; 2006.

  4. Cuevas L, Shamah T, Rivera J, Moreno LB, Ávila MA, Mendoza AJ. Nutrition. National Survey of Health Nutrition 2006. Results by State, Tamaulipas, Mexico. Cuernavaca, Morelos, México: Instituto Nacional de Salud Pública; 2007.

  5. Wacher-Rodarte NH, Cruz-López M, Kumate-Rodríguez J. Propuesta para la detección de casos nuevos de diabetes tipo 2 en México. In: Martínez H, Villasís MA, Torres J, Gómez A, editors. Las múltiples facetas de la investigación en salud 4. México: Instituto Mexicano del Seguro Social: 2005. p. 35-49.

  6. Sociedad Mexicana de Nutrición y Endocrinología. Escrutinio, diagnóstico, evaluación inicial y seguimiento del paciente con diabetes mellitus tipo 2. Rev Endocrinol Nutr 2004;12:2:s8-s14.

  7. Vozarova B, Stefan N, Lindsay RS, Saremi A, Pratley RE, Bogardus C, et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002;51:1889-1895.

  8. Nannipieri M, González C, Baldi S, Posadas R, Williams K, Haffner SM, Ferrannini E. Liver enzimes, the metabolic syndrome, and incident diabetes. Diabetes Care 2005;28: 1757-1762.

  9. Cho NH, Jang HC, Kim HR, Lee HK, Chan JCN, Lim S. Abnormal liver function test predicts type 2 diabetes. Diabetes Care 2007;30:10:2566-2568.

  10. Wannamethee SG, Shaper AG, Lennon L, Whincup PH. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care 2005;28: 12:2913-2918.

  11. National Institute for Alcohol Abuse and Alcoholism. Clinicians Guide 2005. Available at http://pubs.niaaa.nih.gov/ publications/Practitioner/CliniciansGuide2005/clinicians _guide.htm

  12. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009;32(Suppl 1):s62-s67.

  13. World Health Organization. Global database on body mass index. An interactive surveillance tool for monitoring nutrition transition. Available at www.who.int/bmi/index.jsp

  14. Instituto Mexicano del Seguro Social. Guía de práctica clínica. Diagnóstico y tratamiento de la hipertensión arterial en el primer nivel de atención. México: IMSS; 2010. Available at http://www.imss.gob.mx/NR/rdonlyres/2281F198-27B5- 49C6-B12E-8ED4C74701B4/0/GER_HIPERTENSION_ 1ERN.pdf

  15. Aguilar-Salinas CA, Gómez-Pérez FJ, Lerman-Garber I, Vázquez-Chávez C, Pérez-Méndez O, Posadas-Romero C. Diagnóstico y tratamiento de las dislipidemias: posición de la sociedad mexicana de endocrinología y nutrición. Rev Endocrinol Nutr 2004;12:1:7-41.

  16. Pearson TA, Mensah GA, Alexander RW, et al. AHA/CDC Scientific Statement. Markers of inflammation and cardiovascular disease. Circulation 2003;107:499-511.

  17. Hanley AJ, Williams K, Festa A, et al. Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2004;53:2623- 2632.

  18. Doi Y, Kubo M, Yonemoto K, Ninomiya T, Iwase M, Tanizaki Y, et al. Liver enzymes as a predictor for incident diabetes in a Japanese population: the Hisayama study. Obesity 2007;15:1841-1850.

  19. Jeon CY, Lokken RP, Hu FB, Van Dam RM. Physical activity of moderate intensity and risk of type 2 diabetes. A systematic review. Diabetes Care 2007;30:744-752.

  20. Kobaissi HA, Weigensberg MJ, Ball GDC, Cruz ML, Shaibi GQ, Goran MI. Relation between acanthosis nigricans and insulin sensitivity in overweight Hispanic children at risk for type 2 diabetes. Diabetes Care 2004;27:1412-1416

  21. Thomas AS, Greene LF, Ard JD, Oster RA, Darnell BE, Gower BA. Physical activity may facilitate diabetes prevention in adolescents. Diabetes Care 2009;32:9-13.

  22. Loguercio C, De Simone T, D’Auria MV, De Sio I, Federico A, Tuccillo C, Abbatecola A, et al. Italian AISF clinical group: Non-alcoholic fatty liver disease: a multicentre clinical study by the Italian association for the study of the liver. Dig Liver Dis 2004;36:398-405.

  23. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50:1844-1850.

  24. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004; 279:3245-3253.

  25. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 2004;24:816-823.

  26. Lee DH, Blomhoff R, Jacobs DR Jr. Is serum gamma glutamyltransferase a marker of oxidative stress? Free Radic Res 2004;38:535-539.

  27. Lee DH, Ha MH, Kim JH, Christiani DC, Gross MD, Steffes M, et al. Gamma-glutamyltransferase and diabetes: 4 yr follow-up. Diabetologia 2003;46:359-364.

  28. Lee DH, Jacobs DR Jr, Gross M, Kiefe CI, Roseman J, Lewis CE, et al. Gammaglutamyltransferase is a predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem 2003;49:1358-1366.

  29. Nakanishi N, Nishina K, Li W, Sato M, Suzuki K, Tatara K. Serum gamma-glutamyltransferase and development of impaired fasting glucose or type 2 diabetes in middle-aged Japanese men. J Intern Med 2003;254:287-295.

  30. Kerner A, Avizohar O, Sella R, Bartha P, Zinder O, Markiewicz W, et al. Association between elevated liver enzymes and C-reactive protein possible hepatic contribution to systemic inflammation in the metabolic syndrome Arterioscler Thromb Vasc Biol 2005;25:193-197.

  31. Andre P, Balkau B, Born C, Charles MA, Eschwege E; D.E.S.I.R. Study Group. Three-year increase of gammaglutamyltransferase level and development of type 2 diabetes in middle-aged men and women: the D.E.S.I.R. cohort. Diabetologia 2006;49:2599-2603.




2020     |     www.medigraphic.com